Regeneron Pharmaceuticals
REGN
$2.11 (0.26%)
1D
1W
3M
1Y
5Y
ALL
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
The Motley Fool • 3 days ago • REGN
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
Seeking Alpha • 4 days ago • REGN
Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare
Market Watch • 8 days ago • REGN
Regeneron's pricing deal with federal government may have ‘far-reaching consequences,' analysts say
Forbes • 12 days ago • REGN
Is Regeneron Stock Fully Valued At $820?
Market Watch • 15 days ago • REGN
Regeneron CFO Landry to retire, top accountant Fenimore to become CFO
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.
